Health innovation has an important part to play in managing the burden of diabetes and CHD in Scotland; saving and improving the quality of patients lives, according to a new economic report published today.
The report, The Future Burden of CHD and Diabetes in Scotland: The Value of Healthcare Innovation, by the independent economic consultancy group NERA accesses how innovation in health care can help to reduce the pressure on Scottish health care resources from CHD and diabetes.
The report’s key findings include:
Increased prescribing of statins for CHD could save 4,000 lives over the next 5 years, prevent over 2500 heart bypasses and over 3,000 angioplasties.
Around 197,000 hospital bed days could be saved with the effective use of medicines to treat CHD over the next 5 years
The cost of CHD in Scotland in 2005 is likely to be £1.8 billion and it is predicted to rise to £2.1 billion in 2025. Almost £50 million could be saved with the increased use of statins over 5 years.
Tight management of Type 2 diabetes could save over 91,000 bed days a year in 2025 and reduce hospital costs by £41 million
Scotland’s economy would save £78 million a year in lost work days by intensive treatment of Type 2 diabetes.
The impact of these diseases on NHSScotland is substantial. Half a million people in Scotland currently have CHD, and 180,000 people require regular treatment costing NHSScotland £451 million. Scotland also has the highest mortality rate from CHD in the UK, with over 14,000 people having died of the disease in 2003. Around 162,000 people have been diagnosed with diabetes in Scotland equating to 3.2 per cent of the population compared to 2.3 per cent for the rest of the UK. The number of people affected by diabetes is expected to rise to 350,000 by 2025.
Jim Eadie, Director of ABPI Scotland said, “Medicines play an important role in offering people affected by CHD and diabetes an improved quality of life as well as helping to reduce the pressure on NHSScotland resources. It is essential that innovative medicines are effectively used across the whole of Scotland to give every patient the best possible outcome.”
The report recognises that Scotland’s ageing population, lifestyle and diet affects the high prevalence of these diseases. However the report points out that managing these diseases effectively will improve the consequences for the patient, reducing the cost to the health service and benefit the economy.
David Clark, Chief Executive of Chest, Heart and Stroke Scotland said, “In spite of recent progress CHD remains one of the major causes of morbidity and mortality in Scotland. Innovations in pharmaceuticals, improved medical care and lifestyle changes all play a vital contribution to reducing the burden of CHD for individuals and society.”
Audrey Birt, National Director Scotland of Diabetes UK said “Scotland faces an increasing challenge from diabetes and its consequences for individuals, NHSScotland and our society as a whole. It is important that we remember that tight control of this disease, as recommended by this report, will only be achieved through education, information and support for those living with diabetes.”
Note to editors
NERA Economic Consulting is an international firm of economists who understand how markets work. It provides economic analysis and advice to corporations, governments, law firms, regulatory agencies, trade associations and international agencies.
NERA has more than 40 years of experience creating strategies, studies, reports, expert testimony, and policy recommendations reflecting their specialisation in industrial and financial economics. NERA’s commitment to deliver unbiased findings has made them widely recognised for their independence.
NERA has a dedicated health and pharmaceutical team drawing on specialists from Europe and the US working on a variety of areas including health reform, health sector modelling, pharmaceutical pricing and reimbursement, economic evaluation, intellectual property and strategic advice.
The Future Burden of CHD and Diabetes in Scotland: The Value of Healthcare Innovation was commissioned by the Association of the British Pharmaceutical Industry (ABPI) Scotland in conjunction with ABPI Scotland’s CHD and Stroke Industry Group and ABPI Scotland’s Diabetes Industry Group.
The Association of the British Pharmaceutical Industry (ABPI) is the trade association for about a hundred companies in the UK producing prescription medicines. Its member companies research, develop, manufacture and supply more than 90 per cent of the medicines prescribed through the National Health Service (NHS).
For further information, please contact: ABPI Press Office 020 7747 1410